This approach demonstrates multiple clinical benefits: (a) established safety in asymptomatic mCRPC patients, (b) delayed cancer progression, (c) sustained prostate-specific antigen suppression, and (d) restored sensitivity to subsequent combined androgen blockade therapy (40, 41). The gene discussed is KLK3; the disease is cancer.